Drug intelligence / Profile preview

MYL-1401A

Development stage: Unknown
Lead developer: Biocon
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

**MYL-1401A** is a recombinant human IgG1 monoclonal antibody biosimilar to adalimumab (Humira), developed by Biocon and originally partnered with Mylan (now part of Viatris). It functions as a tumor necrosis factor alpha (TNFα) inhibitor, binding to TNFα to prevent activation of TNF receptors, thereby downregulating inflammatory responses in autoimmune conditions. Primary evaluations have focused on rheumatoid arthritis (Phase III) and plaque psoriasis (Phase III, with efficacy, safety, and pharmacokinetics data released), administered subcutaneously as an injectable therapy.[1][3][5][14]

Other names: adalimumab biosimilar

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on MYL-1401A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MYL-1401A.

Explore the full profile